Cytochrome P450/redox partner fusion enzymes: biotechnological and toxicological prospects

Bibliography

• GUENGERICH FP: Human cytochrome P450 enzymes. In: Cytochrome P450: Structure, Mechanism and Biochemistry. Ortiz de Montellano PR (Ed.), Kluwer Academic/Plenum Publishers, New York, USA (2005):377-530.
   Google Scholar
• MCGINNITY DF, RILEY RJ: Predicting drug pharmacokinetics from in vitro metabolism studies. Biochem. Soc. Trans. (2005) 29:135-139.
   Google Scholar
• MUNRO AW, GIRVAN HM, MCLEAN KJ: Cytochrome P450-redox partner fusion enzymes. Biochim. Biophys. Acta (2007) 1770:345-359.
   PubMed Web of Science ®Google Scholar
• MAHGOUB A, IDLE JR, DRING LG et al.: Polymorphic hydroxylation of debrisoquinone in man. Lancet (1977) 2:584-586.
   PubMed Web of Science ®Google Scholar
• WANG RW, KARI PH, LU AY et al.: Biotransformation of lovastatin. IV. Identification of cytochrome P450 3A proteins as the major enzymes responsible for the oxidative metabolism of lovastatin in rat and human liver microsomes. Arch. Biochem. Biophys. (1991) 290:355-361.
   PubMed Web of Science ®Google Scholar
• KUNITOH S, IMAOKA S, HIROI T et al.: Acetaldehyde as well as ethanol is metabolised by human CYP2E1. J. Pharmacol. Exp. Ther. (1997) 280:527-532.
   PubMed Web of Science ®Google Scholar
• KOREEDA M, MOORE PD, WISLOCKI PG et al.: Binding of benzo[a]pyrene 7,8-diol-9,10-epoxides to DNA, RNA, and protein of mouse skin occurs with high stereoselectivity. Science (1978) 199:778-781.
   PubMed Web of Science ®Google Scholar
• BOOCOCK DJ, BROWN K, GIBBS AH et al.: Identification of human CYP forms involved in the activation of tamoxifen and irreversible binding to DNA. Carcinogenesis (2002) 23:1897-1901.
   PubMed Web of Science ®Google Scholar
• MUNRO AW, LINDSAY JG: Bacterial cytochromes P-450. Mol. Microbiol. (1996) 20:1115-1125.
   PubMed Web of Science ®Google Scholar
• SLIGAR SG, CINTI DL, GIBSON GG, SCHENKMAN JB: Spin state control of the hepatic cytochrome P450 redox potential. Biochem. Biophys. Res. Commun. (1979) 90:925-932.
   PubMed Web of Science ®Google Scholar
• DAFF SN, CHAPMAN SK, TURNER KL et al.: Redox control of the catalytic cycle of flavocytochrome P-450 BM3. Biochemistry (1997) 36:13816-13823.
   PubMed Web of Science ®Google Scholar
• DENISOV IG, MAKRIS TM, SLIGAR SG, SCHLICHTING I: Structure and chemistry of cytochrome P450. Chem. Rev. (2005) 105:2253-2277.
   PubMed Web of Science ®Google Scholar
• NEWCOMB M, ZHANG R, CHANDRASENA RE et al.: Cytochrome P450 compound I. J. Am. Chem. Soc. (2006) 128:4580-4581.
   PubMed Web of Science ®Google Scholar
• MUNRO AW, LEYS DG, MCLEAN KJ et al.: P450 BM3: the very model of a modern flavocytochrome. Trends Biochem. Sci. (2002) 27:250-257.
   PubMed Web of Science ®Google Scholar
• MURATALIEV MB, FEYEREISEN R, WALKER FA: Electron transfer by diflavin reductases. Biochim. Biophys. Acta (2004) 1698:1-26.
   PubMed Web of Science ®Google Scholar
• HUBBARD PA, SHEN AL, PASCHKE R et al.: NADPH-cytochrome P450 oxidoreductase. Structural basis for hydride and electron transfer. J. Biol. Chem. (2001) 276:29163-29170.
   PubMed Web of Science ®Google Scholar
• MUNRO AW, GIRVAN HM, MCLEAN KJ: Variations on a (t)heme – novel mechanisms, redox partners and catalytic functions in the cytochrome P450 superfamily. Nat. Prod. Rep. (2007) 24:585-609.
   PubMed Web of Science ®Google Scholar
• LAWSON RJ, VON WACHENFELDT C, HAQ I et al.: Expression and characterization of the two flavodoxin proteins of Bacillus subtilis, YkuN and YkuP: biophysical properties and interactions with cytochrome P450 BioI. Biochemistry (2004) 43:12390-12409.
   PubMed Web of Science ®Google Scholar
• GREEN AJ, MUNRO AW, CHEESMAN MR et al.: Expression, purification and characterisation of a Bacillus subtilis ferredoxin: a potential electron transfer donor to cytochrome P450 BioI. J. Inorg. Biochem. (2003) 93:92-99.
   PubMed Web of Science ®Google Scholar
• SEVRIOUKOVA IF, GARCIA C, LI H et al.: Crystal structure of putidaredoxin, the [2Fe-2S] component of the P450cam monooxygenase system from Pseudomonas putida. J. Mol. Biol. (2003) 333:377-392.
   PubMed Web of Science ®Google Scholar
• DAIBER A, SHOUN H, ULLRICH V: Nitric oxide reductase (P450nor) from Fusarium oxysporum. J. Inorg. Biochem. (2005) 99:185-193.
   PubMed Web of Science ®Google Scholar
• IMAI Y, MATSUNAGA I, KUSENOSE E, ICHIHARA K: Unique heme environment at the putative distal region of hydrogen peroxide-dependent fatty acid α-hydroxylase from Sphingomonas paucimobilis (peroxygenase P450SPα). J. Biochem. (2000) 128:189-194.
   PubMed Web of Science ®Google Scholar
• NOBLE MA, MILES CS, CHAPMAN SK et al.: Roles of key active-site residues in flavocytochrome P450 BM3. Biochem. J. (1999) 339:371-379.
   PubMed Web of Science ®Google Scholar
• JACKSON CJ, LAMB DC, MARCZYLO TH et al.: A novel sterol 14α-demethylase/ferredoxin fusion protein (MCCYP51FX) from Methylococcus capsulatus represents a new class of the cytochrome P450 superfamily. J. Biol. Chem. (2002) 277:46959-46965.
   PubMed Web of Science ®Google Scholar
• RYLOTT EL, JACKSON RG, EDWARDS J et al.: An explosive-degrading cytochrome P450 activity and its targeted application for the phytoremediation of RDX. Nat. Biotechnol. (2006) 24:216-219.
   PubMed Web of Science ®Google Scholar
• NARHI LO, FULCO AJ: Identification and characterization of two functional domains in cytochrome P-450BM-3, a catalytically self-sufficient monooxygenase induced by barbiturates in Bacillus megaterium. J. Biol. Chem. (1987) 262:6683-6690.
   PubMed Web of Science ®Google Scholar
• MILES JS, MUNRO AW, ROSPENDOWSKI BN et al.: Domains of the catalytically self-sufficient cytochrome P-450 BM-3. Genetic construction, overexpression, purification and spectroscopic characterization. Biochem. J. (1992) 288:503-509.
   PubMed Web of Science ®Google Scholar
• GUSTAFSSON MC, ROITEL O, MARSHALL KR et al.: Expression, purification, and characterization of Bacillus subtilis cytochromes P450 CYP102A2 and CYP102A3: flavocytochrome homologues of P450 BM3 from Bacillus megaterium. Biochemistry (2004) 43:5474-5487.
   PubMed Web of Science ®Google Scholar
• DE MOT R, PARRET AH: A novel class of self-sufficient cytochrome P450 monooxygenases in prokaryotes. Trends Microbiol. (2002) 10:502-508.
   PubMed Web of Science ®Google Scholar
• GOVINDARAJ S, POULOS TL: Role of the linker region connecting the reductase and heme domains in cytochrome P450BM-3. Biochemistry (1996) 34:11221-11226.
   Web of Science ®Google Scholar
• ROBERTS GA, CELIK A, HUNTER DJ et al.: A self-sufficient cytochrome P450 with a primary structural organization that includes a flavin domain and a [2Fe-2S] redox center. J. Biol. Chem. (2003) 278:48914-48920.
   PubMed Web of Science ®Google Scholar
• CELIK A, ROBERTS GA, WHITE JH et al.: Probing the substrate specificity of the catalytically self-sufficient cytochrome P450 RhF from a Rhodococcus species. Chem. Commun. (2006) 2006:4492-4494.
   Google Scholar
• MUNRO AW, DAFF S, COGGINS JR et al.: Probing electron transfer in flavocytochrome P-450 BM3 and its component domains. Eur. J. Biochem. (1996) 239:403-409.
   PubMedGoogle Scholar
• LI HY, DARWISH K, POULOS TL: Characterization of recombinant Bacillusmegaterium cytochrome P-450 BM-3 and its two functional domains. J. Biol. Chem. (1991) 266:11909-11914.
   PubMed Web of Science ®Google Scholar
• BODDUPALLI SS, ESTABROOK RW, PETERSON JA: Fatty acid monooxygenation by cytochrome P-450BM-3. J. Biol. Chem. (1990) 265:4233-4239.
   PubMed Web of Science ®Google Scholar
• MUNRO AW, LINDSAY JG, COGGINS JR et al.: Structural and enzymological analysis of the interaction of isolated domains of cytochrome P-450 BM3. FEBS Lett. (1994) 343:70-74.
   PubMed Web of Science ®Google Scholar
• PORTER TD: An unusual yet strongly conserved flavoprotein reductase in bacteria and mammals. Trends Biochem. Sci. (1991) 16:154-158.
   PubMed Web of Science ®Google Scholar
• GOVINDARAJ S, POULOS TL: The domain architecture of cytochrome P450BM-3. J. Biol. Chem. (1997) 272:7915-7921.
   PubMed Web of Science ®Google Scholar
• SMITH GC, TEW DG, WOLF CR: Dissection of NADPH-cytochrome P450 oxidoreductase into distinct functional domains. Proc. Natl. Acad. Sci. USA (1994) 91:8710-8714.
   PubMed Web of Science ®Google Scholar
• LI H, POULOS TL: The structure of the cytochrome P450 BM-3 haem domain complexed with the fatty acid substrate, palmitoleic acid. Nat. Struct. Biol. (1997) 4:140-146.
   PubMedGoogle Scholar
• HAINES DC, TOMCHICK DR, MACHIUS M, PETERSON JA: Pivotal role of water in the mechanism of P450 BM-3. Biochemistry (2001) 40:13456-13465.
   PubMed Web of Science ®Google Scholar
• GIRVAN HM, MARSHALL KR, LAWSON RJ et al.: Flavocytochrome P450 BM3 mutant A264E undergoes substrate-dependent formation of a novel heme iron ligand set. J. Biol. Chem. (2004) 279:23274-23286.
   PubMed Web of Science ®Google Scholar
• JOYCE HM, GIRVAN HM, MUNRO AW, LEYS D: A single mutation in cytochrome P450 BM3 induces the conformational rearrangement seen upon substrate binding in the wild-type enzyme. J. Biol. Chem. (2004) 279:23287-23293.
   PubMed Web of Science ®Google Scholar
• KLEIN ML, FULCO AJ: Critical residues involved in FMN binding and catalytic activity in cytochrome P450BM-3. J. Biol. Chem. (1993) 268:7553-7561.
   PubMed Web of Science ®Google Scholar
• GIRVAN HM, SEWARD HE, TOOGOOD HS et al.: Structural and spectroscopic characterization of P450 BM3 mutants with unprecedented P450 heme iron ligand sets. New heme ligation states influence conformational equilibria in P450 BM3. J. Biol. Chem. (2007) 282:564-572.
   PubMed Web of Science ®Google Scholar
• NEELI R, GIRVAN HM, LAWRENCE A et al.: The dimeric form of flavocytochrome P450 BM3 is catalytically functional as a fatty acid hydroxylase. FEBS Lett. (2005) 579:5582-5588.
   PubMed Web of Science ®Google Scholar
• BLACK SD, MARTIN ST: Evidence for conformational dynamics and molecular aggregation in cytochrome P450 102 (BM-3). Biochemistry (1994) 33:12056-12062.
   PubMed Web of Science ®Google Scholar
• SIDDHANTA U, PRESTA A, FAN B et al.: Domain swapping in inducible nitric-oxide synthase. Electron transfer occurs between flavin and heme groups located on adjacent subunits in the dimer. J. Biol. Chem. (1998) 273:18950-18958.
   PubMed Web of Science ®Google Scholar
• OLIVER CF, MODI S, SUTCLIFFE MJ et al.: A single mutation in cytochrome P450 BM3 changes substrate orientation in a catalytic intermediate and the regiospecificity of hydroxylation. Biochemistry (1997) 36:1567-1572.
   PubMed Web of Science ®Google Scholar
• YEOM H, SLIGAR SG, LI H et al.: The role of Thr268 in oxygen activation of cytochrome P450BM-3. Biochemistry (1995) 34:14733-14740.
   PubMed Web of Science ®Google Scholar
• OST TW, MILES CS, MUNRO AW et al.: Phenylalanine 393 exerts thermodynamic control over the heme of flavocytochrome P450 BM3. Biochemistry (2001) 40:13421-13429.
   PubMed Web of Science ®Google Scholar
• PALMER CN, GUSTAFSSON MC, DOBSON H et al.: Adaptive responses to fatty acids are mediated by the regulated expression of cytochromes P450. Biochem. Soc. Trans. (1999) 27:374-378.
   PubMed Web of Science ®Google Scholar
• NAKAYAME N, TAKEMAE A, SHOUN H: Cytochrome P450foxy, a catalytically self-sufficient fatty acid hydroxylase of the fungus Fusarium oxysporum. J. Biochem. (1996) 119:435-440.
   PubMed Web of Science ®Google Scholar
• KITAZUME T, TANAKA A, TAKAYA N et al.: Kinetic analysis of saturated fatty acids by recombinant P450foxy produce by an Escherichia coli expression system. Eur. J. Biochem. (2002) 269:2075-2082.
   PubMedGoogle Scholar
• SEO JA, PROCTOR RH, PLATTNER RD: Characterization of four clustered and coregulated genes associated with fumonisin biosynthesis in Fusarium verticillioides. Fungal Genet. Biol. (2001) 34:155-165.
   PubMed Web of Science ®Google Scholar
• OST TW, MILES CS, MURDOCH J et al.: Rational re-design of the substrate binding site of flavocytochrome P450 BM3. FEBS Lett. (2000) 486:173-177.
   PubMed Web of Science ®Google Scholar
• CARMICHAEL AB, WONG LL: Protein engineering of Bacillus megaterium CYP102. The oxidation of polycyclic aromatic hydrocarbons. Eur. J. Biochem. (2001) 268:3117-3125.
   PubMedGoogle Scholar
• GRAHAM-LORENCE S, TRUAN G, PETERSON JR et al.: An active site substitution, F87V, converts cytochrome P450 BM-3 into a regio- and stereoselective (14S, 15R)-arachidonic acid epoxygenase. J. Biol. Chem. (1997) 272:1127-1135.
   PubMed Web of Science ®Google Scholar
• MEINHOLD P, PETERS MW, CHEN MM et al.: Direct conversion of ethane to ethanol by engineered cytochrome P450 BM3. ChemBiochem (2005) 6:1765-1768.
   PubMed Web of Science ®Google Scholar
• PETERS MW, MEINHOLD P, GLIEDER A, ARNOLD FH: Regio- and enantioselective alkane hydroxylation with engineered cytochromes P450 BM-3. J. Am. Chem. Soc. (2003) 125:13442-13450.
   PubMed Web of Science ®Google Scholar
• KUBO T, PETERS MW, MEINHOLD P, ARNOLD FH: Enantioselective epoxidation of terminal alkenes to (R)- and (S)-epoxides by engineered cytochromes P450 BM-3. Chemistry (2006) 12:1216-1220.
   PubMed Web of Science ®Google Scholar
• SENG WONG T, ARNOLD FH, SCHWANEBERG U: Laboratory evolution of cytochrome P450 BM-3 monooxygenase for organic cosolvents. Biotechnol. Bioeng. (2004) 85:351-358.
   PubMed Web of Science ®Google Scholar
• GLIEDER A, FARINAS ET, ARNOLD FH: Laboratory evolution of a soluble, self-sufficient, highly active alkane hydroxylase. Nat. Biotechnol. (2002) 20:1135-1139.
   PubMed Web of Science ®Google Scholar
• LENTZ O, FEENSTRA A, HABICHER T et al.: Altering the regioselectivity of cytochrome P450 CYP102A3 of Bacillus subtilis by using a new versatile assay system. ChemBiochem (2006) 7:345-350.
   PubMed Web of Science ®Google Scholar
• AXARLI I, PRIGIPAKI A, LABROU NE: Engineering the substrate specificity of cytochrome P450 CYP102A2 by directed evolution: production of an efficient enzyme for bioconversion of fine chemicals. Biomol. Eng. (2005) 22:81-88.
   PubMedGoogle Scholar
• LI QS, SCHWANEBERG U, FISCHER M et al.: Rational evolution of a chain-specific cytochrome P-450 BM-3 variant. Biochim. Biophys. Acta (2001) 1545:114-121.
   PubMed Web of Science ®Google Scholar
• SOWDEN RJ, YASMIN S, REES NH et al.: Biotransformation of the sesquiterpene (+)-valencene by cytochrome P450cam and P450BM-3. Org. Biomol. Chem. (2005) 3:57-64.
   PubMed Web of Science ®Google Scholar
• SULISTYANINGDYAH WT, OGAWA J, LI QS et al.: Metabolism of polychlorinated dibenzo-p-dioxins by cytochrome P450 BM-3 and its mutant. Biotechnol. Lett. (2004) 26:1857-1860.
   PubMed Web of Science ®Google Scholar
• LI QS, OGAWA J, SCHMID RD, SHIMIZU S: Indole hydroxylation by bacterial cytochrome P450 BM-3 and modulation of activity by cumene hydroperoxide. Biosci. Biotechnol. Biochem. (2005) 69:293-300.
   PubMed Web of Science ®Google Scholar
• KUMAR S, LIU H, HALPERT JR: Engineering of cytochrome P450 3A4 for enhanced peroxide-mediated substrate oxidation using directed evolution and site-directed mutagenesis. Drug Metab. Dispos. (2006) 34:1958-1965.
   PubMed Web of Science ®Google Scholar
• KUMAR S, SUN L, LIU H et al.: Engineering mammalian cytochrome P450 2B1 by directed evolution for enhanced catalytic tolerance to temperature and dimethyl sulfoxide. Protein Eng. Des. Sel. (2006) 19:547-554.
   PubMed Web of Science ®Google Scholar
• MILES CS, OST TW, NOBLE MA et al.: Protein engineering of cytochromes P-450. Biochim. Biophys. Acta (2000) 1543:383-407.
   PubMed Web of Science ®Google Scholar
• STUEHR DJ, SANTOLINI J, WANG ZQ et al.: Update on mechanism and catalytic regulation in the NO synthases. J. Biol. Chem. (2004) 279:36167-36170.
   PubMed Web of Science ®Google Scholar
• DUNFORD AJ, RIGBY SE, HAY S et al.: Conformational and thermodynamic control of electron transfer in neuronal nitric oxide synthase. Biochemistry (2007) 46:5018-5029.
   PubMed Web of Science ®Google Scholar
• FISHER CW, SHET MS, CAUDLE CA et al.: High level expression in Escherichia coli of enzymatically active fusion proteins containing the domains of mammalian cytochromes P450 and NADPH-cytochrome P450 reductase flavoprotein. Proc. Natl. Acad. Sci. USA (1992) 89:10817-10821.
   PubMed Web of Science ®Google Scholar
• CHAURASIA CS, ALTERMAN MA, LIU P, HANZLIK RP: Biochemical characterization of lauric acid ω-hydroxylation by a CYP4A1/NADPH-cytochrome P450 reductase fusion protein. Arch. Biochem. Biophys. (1995) 317:161-169.
   PubMed Web of Science ®Google Scholar
• CHUN YJ, SHIMADA T, GUENGERICH FP: Construction of a human cytochrome P450 1A1:rat NADPH-cytochrome P450 reductase fusion protein cDNA and expression in Escherichia coli, purification, and catalytic properties of the enzyme in bacterial cells and after purification. Arch. Biochem. Biophys. (1996) 330:48-58.
   PubMed Web of Science ®Google Scholar
• PARIKH A, GUENGERICH FP: Expression, purification and characterization of a catalytically active human cytochrome P450 1A2:rat NADPH-cytochrome P450 reductase fusion protein. Protein Expr. Purif. (1997) 9:346-354.
   PubMed Web of Science ®Google Scholar
• DEENI YY, PAINE MJ, AYRTON AD et al.: Expression, purification and biochemical characterization of a human cytohrome P450 CYP2D6-NADPH cytochrome P450 reductase fusion protein. Arch. Biochem. Biophys. (2001) 396:16-24.
   PubMed Web of Science ®Google Scholar
• DODHIA VR, FANTUZZI A, GILARDI G: Engineering human cytochrome P450 enzymes into catalytically self-sufficient chimeras using molecular lego. J. Biol. Inorg. Chem. (2006) 11:903-916.
   PubMed Web of Science ®Google Scholar
• FUZIWARA S, SAGAMI I, ROZHKOVA E et al.: Catalytically functional chimeras of P450 BM3 and nitric oxide synthase. J. Inorg. Biochem. (2002) 91:515-526.
   PubMed Web of Science ®Google Scholar
• GILEP AA, GURYEV OL, USANOV SA, ESTABROOK RW: Reconstitution of the enzymatic activities of cytochrome P450s using recombinant flavocytochromes containing rat cytochrome b5 fused to NADPH-cytochrome P450 reductase with various membrane-binding segments. Arch. Biochem. Biophys. (2001) 390:215-221.
   PubMed Web of Science ®Google Scholar
• GILEP AA, GURYEV OL, USANOV SA, ESTABROOK RW: Expression, purification, and physical properties of recombinant flavocytochrome fusion proteins containing rat cytochrome b5 linked to NADPH-cytochrome P450 reductase by different membrane-binding segments. Arch. Biochem. Biophys. (2001) 390:222-234.
   PubMed Web of Science ®Google Scholar
• SIBBESEN O, DE VOSS JJ, ORTIZ DE MONTELLANO PR: Putidaredoxin reductase-putidaredoxin-cytochrome P450cam triple fusion protein. Construction of a self-sufficient Escherichia coli catalytic system. J. Biol. Chem. (1996) 271:22462-22469.
   PubMed Web of Science ®Google Scholar
• GOVINDARAJ S, POULOS TL: Probing the structure of the linker connecting the reductase and heme domains of cytochrome P450BM-3 using site-directed mutagenesis. Protein Sci. (1996) 5:1389-1393.
   PubMed Web of Science ®Google Scholar
• STROUP D, RAMSARAN JR: Cholesterol 7-α-hydroxylase is phosphorylated at multiple amino acids. Biochem. Biophys. Res. Commun. (2005) 329:957-965.
   PubMed Web of Science ®Google Scholar
• ZOU MH: Peroxynitrite and protein tyrosine nitration of prostacyclin synthase. Prostaglandins Other Lipid Mediat. (2007) 82:119-127.
   PubMed Web of Science ®Google Scholar
• QUARONI LG, SEWARD HE, MCLEAN KJ et al.: Interaction of nitric oxide with cytochrome P450 BM3. Biochemistry (2004) 43:16416-16431.
   PubMed Web of Science ®Google Scholar
• MUNRO AW, LINDSAY JG, COGGINS JR et al.: NADPH oxidase activity of cytochrome P-450 BM3 and its constituent reductase domain. Biochim. Biophys. Acta (1995) 1231:255-264.
   PubMed Web of Science ®Google Scholar
• DI NARDO G, FANTUZZI A, SIDERI A et al.: Wild-type CYP102A1 as a biocatalyst: turnover of drugs usually metabolised by human liver enzymes. J. Biol. Inorg. Chem. (2007) 12:313-323.
   PubMed Web of Science ®Google Scholar
• VAN VUGT-LUSSENBURG BMA, STJERNSCHANTZ E, LASTDRAGER J et al.: Identification of critical residues in novel drug metabolising mutants of cytochrome P450 BM3 using random mutagenesis. J. Med. Chem. (2007) 50:455-461.
   PubMed Web of Science ®Google Scholar
• OTEY CR, BANDARA G, LALONDE J et al.: Preparation of human metabolites of propranolol using laboratory evolved bacterial cytochromes P450. Biotechnol. Bioeng. (2006) 93:494-499.
   PubMed Web of Science ®Google Scholar
• LANDWEHR M, HOCHREIN L, OTEY CR et al.: Enantioselective α-hydroxylation of 2-arylacetic acid derivatives and buspirone catalyzed by engineered cytochrome P450 BM-3. J. Am. Chem. Soc. (2006) 128:6058-6059.
   PubMed Web of Science ®Google Scholar
• TYCHOPOULOS M, CORCOS L, GENNE P et al.: A virus-directed enzyme prodrug therapy (VDEPT) strategy for lung cancer using a CYP2B6/NADPH-cytochrome P450 reductase fusion protein. Cancer Gene Ther. (2005) 12:497-508.
   PubMed Web of Science ®Google Scholar
• BERNHARDT R: Cytochromes P450 as versatile biocatalysts. J. Biotechnol. (2006) 124:128-145.
   PubMed Web of Science ®Google Scholar
• PERERA R, SONO M, SIGMAN JA et al.: Neutral thiol as a proximal ligand to ferrous heme iron: implications for heme proteins that lose cysteine thiolate ligation on reduction. Proc. Natl. Acad. Sci. USA (2003) 100:3641-3646.
   PubMed Web of Science ®Google Scholar
• DUNFORD AJ, MCLEAN KJ, SABRI M et al.: Rapid P450 heme iron reduction by laser photoexcitation of Mycobacterium tuberculosis CYP121 and CYP51B1. Analysis of CO complexation reactions and reversibility of the P450/P420 equilibrium. J. Biol. Chem. (2007) 282:24816-24824.
   PubMed Web of Science ®Google Scholar
• EIBEN S, BARTELMAS H, URLACHER VB: Construction of a thermostable cytochrome P450 chimera derived from self-sufficient mesophilic parents. Appl. Microbiol. Biotechnol. (2007) 75:1055-1061.
   PubMed Web of Science ®Google Scholar
• LEBRUN LA, HOCH U, ORTIZ DE MONTELLANO PR: Autocatalytic mechanism and consequences of covalent heme attachment in the cytochrome P4504A family. J. Biol. Chem. (2002) 277:12775-12761.
   Google Scholar
• MAURER SC, SCHULZE H, SCMID RD, URLACHER VB: Immobilisation of P450BM-3 and an NADP(+) cofactor recycling system: Towards a technical application of heme-containing monooxygenases in fine chemical synthesis. Adv. Synth. Catal. (2003) 345:802-810.
   Web of Science ®Google Scholar
• AXARLI I, PRIGIPAKI A, LABROU NE: Engineering the substrate specificity of cytochrome P450 CYP102A2 by directed evolution: production of an efficient enzyme for bioconversion of fine chemicals. Biomol. Eng. (2005) 22:81-88.
   PubMedGoogle Scholar
• CHEFSON A, AUCLAIR K: Progress towards the easier use of P450 enzymes. Mol. Biosyst. (2006) 2:462-469.
   PubMed Web of Science ®Google Scholar
• LU Y, MEI L: Co-expression of P450 BM3 and glucose dehydrogenase by recombinant Escherichia coli and its application in an NADPH-dependent indigo production system. J. Ind. Microbiol. Biotechnol. (2007) 34:247-253.
   PubMed Web of Science ®Google Scholar
• NEELI R, ROITEL O, SCUTTON NS, MUNRO AW: Switching pyridine nucleotide specificity in P450 BM3: mechanistic analysis of the W1046H and W1046A enzymes. J. Biol. Chem. (2005) 280:17634-17644.
   PubMed Web of Science ®Google Scholar
• ESTABROOK RW, FAULKNER KM, SHET MS, FISHER CW: Application of electrochemistry for P450-catalyzed reactions. Methods Enzymol. (1996) 272:44-51.
   PubMed Web of Science ®Google Scholar
• SHIMADA T, FUJII-KURIYAMA Y: Metabolic activation of polycyclic aromatic hydrocarbons to carcinogens by cytochromes P450 1A1 and 1B1. Cancer Sci. (2004) 95:1-6.
   PubMed Web of Science ®Google Scholar
• MINERS JO, BIRKETT DJ: Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br. J. Clin. Pharmacol. (1998) 45:525-538.
   PubMed Web of Science ®Google Scholar
• WIENKERS LC, WURDEN CJ, STORCH E et al.: Formation of (R)-8-hydroxywarfarin in human liver microsomes. A new metabolic marker for the (S)-mephenytoin hydroxylase P4502C19. Drug Metab. Dispos. (1996) 24:610-614.
   PubMed Web of Science ®Google Scholar
• WILLIAMS PA, COSME J, WARD A et al.: Crystal structure of human cytochrome P450 2C9 with bound warfarin. Nature (2003) 424:464-468.
   PubMed Web of Science ®Google Scholar
• CAO PR, BULOW H, DUMAS B, BERNHARDT R: Construction and characterization of a catalytic fusion protein system: P-450(11β)-adrenodoxin reductase-adrenodoxin. Biochim. Biophys. Acta (2000) 1476:253-264.
   PubMed Web of Science ®Google Scholar